PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 144675

[Hepato-biliary sequential scintigraphy-developments, methods and recommendations for its clinical use. Experience in 350 patients with (99m)Tc-Solcoscint-Hepatobida (author's transl)].

H G Reichelt
View original source ↗Export metadata ↓

Abstract

Hepato-biliary sequential scintigraphy is an isotope method in the diagnosis of liver and biliary disease. The value and accuracy of the diagnostic information depends on the development of high resolution gamma cameras and new radiopharmaceuticals; these are described briefly. Our investigations on 350 patients were carried out (99m)Tc-Soloscint-Hepatobida. A number of clinical examples illustrate the scope and value of the examination; from these the indications can be deduced. Hepto-biliary scintigraphy will not replace proven gastro-enterological and radiological methods of investigation, but may be added to these in order to obtain rapid and reliable information. This will be of assitance both to the physician and the patient in deciding which of the more complex methods should be employed next.

Explore related subjects

AcetanilidesBiliary Tract DiseasesCholestasisDiagnosis, DifferentialGastroesophageal RefluxHumansImino AcidsJaundiceLiver DiseasesLiver NeoplasmsPostoperative ComplicationsRadionuclide ImagingTechnetiumJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H G Reichelt. 1977. [Hepato-biliary sequential scintigraphy-developments, methods and recommendations for its clinical use. Experience in 350 patients with (99m)Tc-Solcoscint-Hepatobida (author's transl)].. https://doi.org/10.1055/s-0029-1230735

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.

Methods of uncoupling the DNA binding, cleavage and religation reactions of topoisomerase II were employed to investigate the influence of topoisomerase II-directed drugs on the individual steps in the enzyme's catalytic cycle. A special DNA substrate containing a major topoisomerase II interaction site, which can be cleaved by the enzyme in the absence of any concomitant religation, was used to examine the effect of topoisomerase II-directed agents upon the DNA cleavage reaction. The experiment demonstrated that the topoisomerase II targeting agent Ro 15-0216 stimulates the DNA cleavage reaction extensively, whereas the traditional topoisomerase II inhibitor, mAMSA, has only a minor effect on this reaction. Topoisomerase II trapped in the cleavage complexes can religate to the 3' hydroxyl end of another DNA strand. Using this religation assay, it was demonstrated that the major effect of mAMSA is an inhibition of the enzyme's religation reaction, whereas Ro 15-0216 has no effect on this reaction. Recently, considerable attention has been given to drugs preventing topoisomerase II from introducing DNA cleavages. In the present paper the initial non-covalent DNA binding reaction of topoisomerase II was investigated under conditions excluding enzyme-mediated DNA cleavage. This demonstrated that the anthracycline, aclarubicin, prevents topoisomerase II from performing its initial non-covalent DNA binding reaction and thereby abolishes the DNA cleavage reaction of the enzyme. The results presented here demonstrate that profound differences exist in the mode of action of different agents targeting topoisomerase II, and that the enzyme can be affected by such agents at both its DNA binding, cleavage and religation subreactions.

Acetanilides↗
PubMed1992

Neurochemical evidence for a neuronal GABAergic system in the rat sympathetic superior cervical ganglion.

Some characteristics of gamma aminobutyric acid (GABA) uptake and release in rat superior cervical ganglion (SCG) were investigated. Kinetic analysis of GABA uptake indicated the existence of both high affinity (Km = 18.6 microM) and low affinity (Km = 485 microM) uptake systems. 3H-GABA influx was decreased by inhibitors of glial (beta-alanine), neuronal (2,4-diaminobutyric acid, DABA), or glial and neuronal GABA uptake (nipecotic acid). 3H-GABA efflux was elicited by K+ depolarization in a dose-dependent manner, an effect unaltered by severing the preganglionic nerve fibers. Superfusion of SCG explants with DABA or beta-alanine resulted in increased 3H-GABA efflux from tissue, an effect amplified by the absence of calcium in the superfusion medium. 3H-GABA loading in the presence of DABA, but not in the presence of beta-alanine, resulted in abolition of K(+)-elicited 3H release. At 20 mM, but not at 50 mM K+, the release of 3H-GABA was inhibited by replacing Ca2+ by Mg2+ and by adding EGTA, or by incubating SCG in the presence of the Ca(2+)-channel blocker verapamil. Veratrine evoked GABA release in Ca(2+)-independent manner. None of several putative SCG autacoids or agonists (nicotine, muscarine, norepinephrine, dopamine, serotonin, baclofen, muscimol) significantly modified GABA release.

Acetanilides↗